Dr. Fernandez is a board-certified Obstetrician & Gynecologist with subspecialty in Oncology, and expertise in molecular biology, HPV and cervical cancer. She is an award-winning executive and author with over 3 decades of experience in healthcare, academia, and the pharmaceutical and biotechnology industries. She has co-authored more tha
Dr. Fernandez is a board-certified Obstetrician & Gynecologist with subspecialty in Oncology, and expertise in molecular biology, HPV and cervical cancer. She is an award-winning executive and author with over 3 decades of experience in healthcare, academia, and the pharmaceutical and biotechnology industries. She has co-authored more than 60 scientific publications including topics involving women's health notably HPV vaccines, and cervical cancer screening. Her success in leading clinical development, R & D, and Medical Affairs at global, regional, and national levels while at major pharma companies, GSK and Takeda will accelerate OncoGenesis’ paths into key markets. Dr. Fernandez is also the co-founder of several oncology therapeutic companies, where she helped secure funding for clinical trials and accelerate cancer drug access in low- and middle-income countries.
Scott brings more than 40 years of medical device and diagnostics industry experience to OncoGenesis. He has served in various senior management positions within OncoGenesis and is a member of the Board of Directors.
Scott's in-depth knowledge includes positions at Johnson & Johnson, 3M Healthcare, and Medtronic. Scott served as CEO of Be
Scott brings more than 40 years of medical device and diagnostics industry experience to OncoGenesis. He has served in various senior management positions within OncoGenesis and is a member of the Board of Directors.
Scott's in-depth knowledge includes positions at Johnson & Johnson, 3M Healthcare, and Medtronic. Scott served as CEO of Bentec Medical, leading to a successful exit to strategic buyers. Scott also served as CEO of start-up Dynatherm Medical bringing the Company from concept to market to successful acquisition by Care Fusion. As President of Oridion Medical, he built market presence and revenues, leading to a successful IPO in Europe. Scott holds a BS in Chemistry from the University of California - Davis and an MBA from the University of California - Irvine.
Peter Gombrich is a serial entrepreneur having successfully founded three medical device companies. Under his leadership, he raised over $200 million and took several companies public.
Prior to founding OncoGenesis, he founded Diamics, a women’s healthcare company focused on cervical cancer screening. From 1992 to 2006, Peter founded and
Peter Gombrich is a serial entrepreneur having successfully founded three medical device companies. Under his leadership, he raised over $200 million and took several companies public.
Prior to founding OncoGenesis, he founded Diamics, a women’s healthcare company focused on cervical cancer screening. From 1992 to 2006, Peter founded and led
AccuMed/Molecular Diagnostics, a cytopathic laboratory products company, which he took public. From 1985 to 1992, he founded and was CEO of CliniCom, a provider of bedside clinical information, which was sold to McKesson. Prior to CliniCom, Peter founded and was CEO and Chairman of Integrated Microcircuits, an outgrowth of St. Jude Medical. From 1976 to 1982, he co-founded St. Jude Medical, the largest heart valve company in the world. Prior to St. Jude, he held various sales and marketing positions in several medical device companies including Medtronic and Beckman Instruments.
Peter holds a BSc degree in electrical engineering from the University of Denver, and an MBA from the University of Denver.
Scott brings more than 40 years of medical device and diagnostics industry experience to OncoGenesis. He has served in various senior management positions within OncoGenesis and is a member of the Board of Directors.
Scott's in-depth knowledge includes positions at Johnson & Johnson, 3M Healthcare, and Medtronic. Scott served as CEO of Be
Scott brings more than 40 years of medical device and diagnostics industry experience to OncoGenesis. He has served in various senior management positions within OncoGenesis and is a member of the Board of Directors.
Scott's in-depth knowledge includes positions at Johnson & Johnson, 3M Healthcare, and Medtronic. Scott served as CEO of Bentec Medical, leading to a successful exit to strategic buyers. Scott also served as CEO of start-up Dynatherm Medical bringing the Company from concept to market to successful acquisition by Care Fusion. As President of Oridion Medical, he built market presence and revenues, leading to a successful IPO in Europe. Scott holds a BS in Chemistry from the University of California - Davis and an MBA from the University of California - Irvine.
Dr. Barcelo is a retired primary care and obstetrics physician and founding member of the Santa Lucia Medical Group. He has served as the Chair of the Department of Family Practice Medicine, Treasurer of the Medical Executive Committee, and a joint conference member at Salinas Valley Memorial Hospital. Dr. Barcelo served as a member of t
Dr. Barcelo is a retired primary care and obstetrics physician and founding member of the Santa Lucia Medical Group. He has served as the Chair of the Department of Family Practice Medicine, Treasurer of the Medical Executive Committee, and a joint conference member at Salinas Valley Memorial Hospital. Dr. Barcelo served as a member of the PRIME-US Advisory Board at UCSF School of Medicine and as the Vice-Chair of the Board of Trustees at Natividad Medical Center.
Tom Umbel has been the President and CEO of Seno Medical since January 2016. Tom led the Business Development efforts at Hologic, the largest dedicated Women’s Health company in the U.S. Tom’s role in managing mergers and acquisitions helped grow Hologic from a small single-product company with $100 million in revenue to a large diversifi
Tom Umbel has been the President and CEO of Seno Medical since January 2016. Tom led the Business Development efforts at Hologic, the largest dedicated Women’s Health company in the U.S. Tom’s role in managing mergers and acquisitions helped grow Hologic from a small single-product company with $100 million in revenue to a large diversified company with more than $2.5 billion during his 15 years. Among his Hologic accomplishments, he led the acquisition of Cytyc ($6.6 billion) and GenProbe. Prior to Hologic, Tom was President of Direct Radiology Corp. (DRC). He led the development and commercialization of the digital x-ray detector technology, which he ultimately sold to Hologic in 1999. This core market-leading digital mammography system is their engine to significant growth. Tom continues to serve on many medical device and diagnostic company boards. Tom holds a BS degree in chemical engineering from Grove City College.
Adam Henry is currently the Senior Vice President of Corporate Development at point-of-care instrument manufacturer, Proof Diagnostics, bringing over 25 years of biotechnology industry experience to the company. Adam’s career functional responsibilities have ranged in scope from corporate strategy, business development (M&A) and marketing
Adam Henry is currently the Senior Vice President of Corporate Development at point-of-care instrument manufacturer, Proof Diagnostics, bringing over 25 years of biotechnology industry experience to the company. Adam’s career functional responsibilities have ranged in scope from corporate strategy, business development (M&A) and marketing, specifically within the molecular diagnostics arena over the past 13 years, to product development, R&D and operations as a product design engineer earlier in his career at Invitrogen (now part of Thermo Fisher Scientific) and Dura Pharmaceuticals (acquired by Elan Pharmaceuticals).
Prior to joining Proof Dx in May 2022, Adam served as Head of Strategy and Business Development at Roche-subsidiary GenMark Dx. Before that, he held senior management roles at Siemens Healthineers, Hologic and Gen-Probe (acquired by Hologic) in strategy, business development and upstream marketing. During his tenure, Gen-Probe launched several highly innovative products including the PANTHER® molecular diagnostic system and the APTIMA® HPV screening assay, and the company’s value doubled, creating nearly $2 billion in value for shareholders, culminating in a successful sale of the business to Hologic in 2012. In total, Adam has facilitated nearly $6 billion in molecular diagnostics transactions since 2009.
Mr. Henry holds an MBA from the UCLA Anderson School of Management and a BS degree in Mechanical Engineering from the University of Nevada.
Assay optimization partner.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.